Advertisement
Advertisement
U.S. markets close in 4 hours 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Mydecine Innovations Group Inc. (MYCO.NE)

NEO - NEO Real Time Price. Currency in CAD
0.6000-0.0300 (-4.76%)
As of 11:35AM EDT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.6300
Open0.6000
Bid0.6000 x N/A
Ask0.6300 x N/A
Day's Range0.6000 - 0.6000
52 Week Range0.4050 - 4.7500
Volume32,001
Avg. Volume54,587
Market Cap8.583M
Beta (5Y Monthly)3.35
PE Ratio (TTM)N/A
EPS (TTM)-4.2300
Earnings DateMar 31, 2023 - Apr 05, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MYCO.NE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      MYDECINE INNOVATIONS GROUP ANNOUNCES COMMON SHARE SUBSCRIPTION AGREEMENT

      Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, today announced that it has entered into a third Common Share Subscription Agreement, effective March 10th, 2023 (the "Subscription Agreement") with a third-party investor in the Company (the "Investor"). The Subscri

    • GlobeNewswire

      Mydecine Announces Debt Settlements

      DENVER, March 06, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce share for debt settlements (the “Debt Settlements”) for debt owed to certain arms-length creditors, service providers and debtors of the Company (collecti

    • CNW Group

      MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

      Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated August 26, 2022 and the subsequent filing o

    Advertisement
    Advertisement